Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2019 Apr;94(2 Suppl 1):20-32.
doi: 10.1590/abd1806-4841.2019940206. Epub 2019 Jun 3.

Consensus on the treatment of autoimmune bullous dermatoses: pemphigus vulgaris and pemphigus foliaceus - Brazilian Society of Dermatology

Affiliations
Practice Guideline

Consensus on the treatment of autoimmune bullous dermatoses: pemphigus vulgaris and pemphigus foliaceus - Brazilian Society of Dermatology

Adriana Maria Porro et al. An Bras Dermatol. 2019 Apr.

Abstract

Pemphigus are intraepidermal autoimmune bullous dermatoses that occur with lesions on the skin and / or mucous membranes. The most frequent types are pemphigus vulgaris and pemphigus foliaceus (classic and endemic). This consensus aims to present a complete and updated review of the treatment of these two more frequent forms of pemphigus, based on the literature and the personal experience of the authors. In moderate and severe cases of pemphigus vulgaris and foliaceus, systemic corticosteroid therapy (prednisone or prednisolone) is the treatment of choice. Adjuvant drugs, usually immunosuppressive drugs (azathioprine, mycophenolate mofetil, methotrexate, cyclophosphamide) may be prescribed as corticosteroid sparers in refractory cases or with contraindications to corticosteroids to minimize side effects. In severe and nonresponsive cases, corticosteroids in the form of intravenous pulse therapy, immunoglobulin and plasmapheresis / immunoadsorption can be administered. Immunobiological drugs, particularly rituximab, appear as a promising alternative. For milder cases, smaller doses of oral corticosteroid, dapsone and topical corticosteroids are options. At the end flowcharts are presented as suggestions for a therapeutic approach for patients with pemphigus vulgaris and pemphigus foliaceus.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: None.

Figures

Figure 1
Figure 1
Treatment algorithm for pemphigus vulgaris PV: pemphigus vulgaris; AZA: azathioprine; MMF: mycophenolate mofetil; IVIG: intravenous immunoglobulin PV only in mucous membrane: Mild: only in oral mucosa/ Moderate: extensive lesions in oral mucosa/ Severe: lesions in oral mucosa and others (for example, esophagus, larynx) PV mucocutaneous: Mild: < 1% de BSA / Moderate: 1 - 10% of BSA / Severe: > 10% of BSA: BSA: body surface area (1% means the sum of injured areas corresponding to the palmar surface of the hand with the five digits) * This severity rating is not definitive and aims to provide initial guidance. Each case should be evaluated individually, including considering the speed of onset and progression of the lesions, comorbidities, contraindications to the use of corticosteroids and response to the treatment applied. ** Prednisone can be replaced by oral prednisolone
Figure 2
Figure 2
Pemphigus foliaceus - treatment algorithm FS - fogo selvagem; BSA - body surface area (1% means the sum of injured areas corresponding to the palm area); CS - corticosteroid; DDS - diamino-diphenil-sulfone or dapsone; AZA - azathioprine; MMF - mycophenolate mofetil; MTX - methotrexate; IVIg - intravenous immunoglobulin.

References

    1. Kridin K, Sagi SZ, Bergman R. Mortality and cause of death in Israeli patients with pemphigus. Acta Derm Venereol. 2017;97:607–611. - PubMed
    1. Hsu DY, Brieva J, Sinha AA, Langan SM, Silverberg JI. Comorbidities and inpatient mortality for pemphigus in the USA. Br J Dermatol. 2016;174:1290–1298. - PubMed
    1. Di Zenzo G, Amber KT, Sayar BS, Müller EJ, Borradori L. Immune response in pemphigus and beyond: progresses and emerging concepts. Semin Immunopathol. 2016;38:57–74. - PubMed
    1. Mahoney MG, Wang Z, Rothenberger K, Koch PJ, Amagai M, Stanley JR. Explanations for the clinical and microscopic localization of lesions in pemphigus foliaceus and vulgaris. J Clin Invest. 1999;103:461–468. - PMC - PubMed
    1. Pan M, Liu X, Zheng J. The pathogenic role of autoantibodies in pemphigus vulgaris. Clin Exp Dermatol. 2011;36:703–707. - PubMed

Publication types

Substances